1. Generics Bulletin

Hikma Manages To Stay Flat In 2022 Despite Generics Pressures

Annual Results See Injectables And Brands Success Offsetting Struggling Generics Unit

 
• By Dave Wallace

As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.

Finger pushing down on scales, balancing piles of coins
Growing returns from injectables and brands are helping to balance downwards pressures on Hikma’s generics business • Source: Shutterstock

Hikma has made no secret of its lowered expectations for its generics business in 2022. Having downgraded its forecasts multiple times over the course of last year (Also see "Hikma Eyes Return To Growth After Further Cutting Generics Forecasts" - Generics Bulletin, 4 August, 2022.), the firm has prepared investors and analysts for a rocky 12-month report.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business